181.38 USD
-6.84 (-3.63%)
181.38 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to ICLR. ICLR was compared to 57 industry peers in the Life Sciences Tools & Services industry. ICLR has an average financial health and profitability rating. ICLR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ICLR was profitable.
ICLR had a positive operating cash flow in the past year.
Each year in the past 5 years ICLR has been profitable.
In the past 5 years ICLR always reported a positive cash flow from operatings.
1.2 Ratios
ICLR has a Return On Assets of 3.63%. This is in the better half of the industry: ICLR outperforms 75.44% of its industry peers.
The Return On Equity of ICLR (6.42%) is better than 75.44% of its industry peers.
ICLR has a better Return On Invested Capital (6.74%) than 75.44% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ICLR is significantly below the industry average of 14.00%.
The last Return On Invested Capital (6.74%) for ICLR is above the 3 year average (5.80%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.63% | ||
| ROE | 6.42% | ||
| ROIC | 6.74% |
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
1.3 Margins
ICLR has a better Profit Margin (7.40%) than 75.44% of its industry peers.
In the last couple of years the Profit Margin of ICLR has declined.
With a decent Operating Margin value of 13.99%, ICLR is doing good in the industry, outperforming 73.68% of the companies in the same industry.
ICLR's Operating Margin has been stable in the last couple of years.
ICLR has a worse Gross Margin (28.15%) than 77.19% of its industry peers.
In the last couple of years the Gross Margin of ICLR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.99% | ||
| PM (TTM) | 7.4% | ||
| GM | 28.15% |
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ICLR is destroying value.
ICLR has less shares outstanding than it did 1 year ago.
The number of shares outstanding for ICLR has been increased compared to 5 years ago.
Compared to 1 year ago, ICLR has an improved debt to assets ratio.
2.2 Solvency
ICLR has an Altman-Z score of 2.13. This is not the best score and indicates that ICLR is in the grey zone with still only limited risk for bankruptcy at the moment.
ICLR has a Altman-Z score of 2.13. This is comparable to the rest of the industry: ICLR outperforms 50.88% of its industry peers.
The Debt to FCF ratio of ICLR is 3.53, which is a good value as it means it would take ICLR, 3.53 years of fcf income to pay off all of its debts.
ICLR's Debt to FCF ratio of 3.53 is fine compared to the rest of the industry. ICLR outperforms 78.95% of its industry peers.
A Debt/Equity ratio of 0.31 indicates that ICLR is not too dependend on debt financing.
ICLR has a Debt to Equity ratio (0.31) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | 3.53 | ||
| Altman-Z | 2.13 |
ROIC/WACC0.75
WACC8.93%
2.3 Liquidity
A Current Ratio of 1.06 indicates that ICLR should not have too much problems paying its short term obligations.
ICLR's Current ratio of 1.06 is on the low side compared to the rest of the industry. ICLR is outperformed by 85.96% of its industry peers.
A Quick Ratio of 1.06 indicates that ICLR should not have too much problems paying its short term obligations.
The Quick ratio of ICLR (1.06) is worse than 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 1.06 |
3. Growth
3.1 Past
ICLR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.99%.
ICLR shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.23% yearly.
Looking at the last year, ICLR shows a decrease in Revenue. The Revenue has decreased by -2.46% in the last year.
ICLR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.17% yearly.
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%
3.2 Future
ICLR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.61% yearly.
The Revenue is expected to grow by 2.38% on average over the next years.
EPS Next Y-4.69%
EPS Next 2Y-1.27%
EPS Next 3Y2.47%
EPS Next 5Y5.61%
Revenue Next Year-2.44%
Revenue Next 2Y-0.9%
Revenue Next 3Y0.9%
Revenue Next 5Y2.38%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 13.75, the valuation of ICLR can be described as correct.
ICLR's Price/Earnings ratio is rather cheap when compared to the industry. ICLR is cheaper than 96.49% of the companies in the same industry.
ICLR is valuated rather cheaply when we compare the Price/Earnings ratio to 27.19, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 13.29 indicates a correct valuation of ICLR.
96.49% of the companies in the same industry are more expensive than ICLR, based on the Price/Forward Earnings ratio.
ICLR is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.88, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.75 | ||
| Fwd PE | 13.29 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ICLR is valued cheaper than 98.25% of the companies in the same industry.
ICLR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ICLR is cheaper than 94.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.36 | ||
| EV/EBITDA | 11.37 |
4.3 Compensation for Growth
ICLR has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.9
EPS Next 2Y-1.27%
EPS Next 3Y2.47%
5. Dividend
5.1 Amount
ICLR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
181.38
-6.84 (-3.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners105.53%
Inst Owner Change0%
Ins Owners0.66%
Ins Owner ChangeN/A
Market Cap13.85B
Revenue(TTM)8.10B
Net Income(TTM)599.48M
Analysts76.67
Price Target209.67 (15.6%)
Short Float %3.68%
Short Ratio2.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.77%
Min EPS beat(2)-1.21%
Max EPS beat(2)-0.34%
EPS beat(4)1
Avg EPS beat(4)-0.63%
Min EPS beat(4)-1.21%
Max EPS beat(4)0.23%
EPS beat(8)1
Avg EPS beat(8)-2.34%
EPS beat(12)2
Avg EPS beat(12)-1.79%
EPS beat(16)5
Avg EPS beat(16)-1.4%
Revenue beat(2)1
Avg Revenue beat(2)0.4%
Min Revenue beat(2)-0.23%
Max Revenue beat(2)1.03%
Revenue beat(4)1
Avg Revenue beat(4)-0.84%
Min Revenue beat(4)-2.61%
Max Revenue beat(4)1.03%
Revenue beat(8)1
Avg Revenue beat(8)-2.24%
Revenue beat(12)1
Avg Revenue beat(12)-2.14%
Revenue beat(16)1
Avg Revenue beat(16)-2.06%
PT rev (1m)-0.06%
PT rev (3m)-4.74%
EPS NQ rev (1m)-0.09%
EPS NQ rev (3m)-4.76%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)-1.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.75 | ||
| Fwd PE | 13.29 | ||
| P/S | 1.71 | ||
| P/FCF | 14.36 | ||
| P/OCF | 12.15 | ||
| P/B | 1.48 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.37 |
EPS(TTM)13.19
EY7.27%
EPS(NY)13.65
Fwd EY7.52%
FCF(TTM)12.63
FCFY6.96%
OCF(TTM)14.93
OCFY8.23%
SpS106.11
BVpS122.25
TBVpS-38.98
PEG (NY)N/A
PEG (5Y)0.9
Graham Number190.47
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.63% | ||
| ROE | 6.42% | ||
| ROCE | 8.53% | ||
| ROIC | 6.74% | ||
| ROICexc | 6.98% | ||
| ROICexgc | 176.34% | ||
| OM | 13.99% | ||
| PM (TTM) | 7.4% | ||
| GM | 28.15% | ||
| FCFM | 11.9% |
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ROICexc(3y)5.97%
ROICexc(5y)8.67%
ROICexgc(3y)88.82%
ROICexgc(5y)90.84%
ROCE(3y)7.34%
ROCE(5y)8.76%
ROICexgc growth 3Y-4.45%
ROICexgc growth 5Y-5.01%
ROICexc growth 3Y27.99%
ROICexc growth 5Y-24.17%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
F-Score6
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | 3.53 | ||
| Debt/EBITDA | 1.89 | ||
| Cap/Depr | 45.31% | ||
| Cap/Sales | 2.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.92% | ||
| Profit Quality | 160.84% | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 1.06 | ||
| Altman-Z | 2.13 |
F-Score6
WACC8.93%
ROIC/WACC0.75
Cap/Depr(3y)27.79%
Cap/Depr(5y)38.09%
Cap/Sales(3y)1.87%
Cap/Sales(5y)1.83%
Profit Quality(3y)130.43%
Profit Quality(5y)205.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
EPS Next Y-4.69%
EPS Next 2Y-1.27%
EPS Next 3Y2.47%
EPS Next 5Y5.61%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%
Revenue Next Year-2.44%
Revenue Next 2Y-0.9%
Revenue Next 3Y0.9%
Revenue Next 5Y2.38%
EBIT growth 1Y-0.88%
EBIT growth 3Y26.12%
EBIT growth 5Y22.99%
EBIT Next Year1.2%
EBIT Next 3Y1.96%
EBIT Next 5Y4.34%
FCF growth 1Y86.71%
FCF growth 3Y15.01%
FCF growth 5Y25.32%
OCF growth 1Y72.39%
OCF growth 3Y15.78%
OCF growth 5Y25.55%
ICON PLC / ICLR FAQ
Can you provide the ChartMill fundamental rating for ICON PLC?
ChartMill assigns a fundamental rating of 5 / 10 to ICLR.
What is the valuation status for ICLR stock?
ChartMill assigns a valuation rating of 6 / 10 to ICON PLC (ICLR). This can be considered as Fairly Valued.
How profitable is ICON PLC (ICLR) stock?
ICON PLC (ICLR) has a profitability rating of 6 / 10.
What is the valuation of ICON PLC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ICON PLC (ICLR) is 13.75 and the Price/Book (PB) ratio is 1.48.
How financially healthy is ICON PLC?
The financial health rating of ICON PLC (ICLR) is 5 / 10.